Partnering opportunity

Actively targeted polymeric micelles for drug and gene delivery

Summary

A Spanish biomedical research networking center has developed innovative micelles as non-viral vectors for drug delivery (in particular for siRNA - small interfering RNA delivery) into cancer cells. They are looking to establish license, research cooperation or technical cooperation agreements.

Partner sought

Patent ready for licensing-out. The research center is seeking industrial partners, either Biotech or Pharma, to: - enter into preclinical R&D collaboration (in vitro and/or in vivo drug testing). - Further development until clinical proof-of-concept.

Description

This Spanish research networking center gathers some of the most important Spanish research groups in biomedicine, located in more than 100 institutions like universities, hospitals, and technological centers distributed around the country. In recent years, nanomedicine has substantially evolved aiming to achieve great advances in diseases treatment and diagnosis. Among the wide range of nanometric vehicles used for drug delivery polymeric micelles have been proved as efficient nanosized (approximately 20 to 200 nm) polymeric self-assembly systems for encapsulating drugs and gene (gene therapy). In this context, gene therapy has appeared as a promising alternative for an effective and more specific treatment of cancer and other complex diseases with an important genetic background. However, the in vivo delivery of oligonucleotides (OGN) has precluded the clinical use of gene-based therapies mainly due to its vulnerability to enzymatic blood degradation, poor cellular uptake, and rapid renal clearance. Therefore, the greatest challenge for a successful clinical application of gene therapy relies on the development of vectors able to condensate negatively charged OGN and to effectively deliver them into the cytoplasm and/or nucleus of target cells. Nowadays, viral vectors are still considered the most efficient, being the most commonly used for gene transfer in both pre-clinical and clinical research, however, the well-known drawbacks related with viral-based vectors such as their immunogenicity, mutagenesis, carcinogenesis, limited cargo loading, and time-consuming/high-cost procedures, boosted the development of safer vehicles using a wide range of lipids and polymers (non-viral vectors). In this sense, the research center has developed new and innovative nanoparticles (micelles) as non-viral vectors which are able to deliver into cells compounds of different nature (drug, gene, other compounds), to be used for therapeutic and non-therapeutic purposes. The center is looking to establish license, research cooperation or technical cooperation agreements with industrial partners.

Advantages and innovations

These innovative nanoparticles are able to deliver into cells compounds of different nature (drug, gene, other compounds), and they can be used for therapeutic (as cancer) and non-therapeutic purposes. These new micelles allow the delivery of oligonucleotides (OGN) in an effective and safety mode into the cells. The micelles composition comprises biodegradable, biocompatible and low immunogenicity block copolymers and a component able to condense siRNA (small interfering RNA) and improve its transfection efficiency and biological activity without toxic cell effects. This composition also allows the micelles to adopt a special self-assembly system in a non-polar solvent. A pharmaceutical composition can be obtained in aqueous media with a therapeutically effective amount of a drug-loaded polymeric micelle together with pharmaceutically acceptable excipients and/or carriers (use as medicament). Multifunctional delivery systems can also be developed. Those systems allow the simultaneous treatment with two or more therapeutic agents, as well as the traceability of the delivered compounds and cells when the delivered compound is a cell marker (e.g. dye)

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company